Cargando…
Viral hepatitis in 2021: The challenges remaining and how we should tackle them
Viral hepatitis results in 1.4 million deaths annually. The World Health Organization (WHO) set an ambitious target to eliminate viral hepatitis by 2030, but significant challenges remain. These include inequalities in access to healthcare, reaching at risk populations and providing access to screen...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8793011/ https://www.ncbi.nlm.nih.gov/pubmed/35125820 http://dx.doi.org/10.3748/wjg.v28.i1.76 |
_version_ | 1784640503489232896 |
---|---|
author | Dunn, Rebecca Wetten, Aaron McPherson, Stuart Donnelly, Mhairi C |
author_facet | Dunn, Rebecca Wetten, Aaron McPherson, Stuart Donnelly, Mhairi C |
author_sort | Dunn, Rebecca |
collection | PubMed |
description | Viral hepatitis results in 1.4 million deaths annually. The World Health Organization (WHO) set an ambitious target to eliminate viral hepatitis by 2030, but significant challenges remain. These include inequalities in access to healthcare, reaching at risk populations and providing access to screening and effective treatment. Stigma around viral hepatitis persists and must be addressed. The WHO goal of global elimination by 2030 is a worthy aim, but remains ambitious and the coronavirus 2019 pandemic undoubtedly has set back progress. This review article will focus on hepatitis A to E, highlighting problems that have been resolved in the field over the past decade, those that remain to be resolved and suggest directions for future problem solving and research. |
format | Online Article Text |
id | pubmed-8793011 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-87930112022-02-03 Viral hepatitis in 2021: The challenges remaining and how we should tackle them Dunn, Rebecca Wetten, Aaron McPherson, Stuart Donnelly, Mhairi C World J Gastroenterol Review Viral hepatitis results in 1.4 million deaths annually. The World Health Organization (WHO) set an ambitious target to eliminate viral hepatitis by 2030, but significant challenges remain. These include inequalities in access to healthcare, reaching at risk populations and providing access to screening and effective treatment. Stigma around viral hepatitis persists and must be addressed. The WHO goal of global elimination by 2030 is a worthy aim, but remains ambitious and the coronavirus 2019 pandemic undoubtedly has set back progress. This review article will focus on hepatitis A to E, highlighting problems that have been resolved in the field over the past decade, those that remain to be resolved and suggest directions for future problem solving and research. Baishideng Publishing Group Inc 2022-01-07 2022-01-07 /pmc/articles/PMC8793011/ /pubmed/35125820 http://dx.doi.org/10.3748/wjg.v28.i1.76 Text en ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
spellingShingle | Review Dunn, Rebecca Wetten, Aaron McPherson, Stuart Donnelly, Mhairi C Viral hepatitis in 2021: The challenges remaining and how we should tackle them |
title | Viral hepatitis in 2021: The challenges remaining and how we should tackle them |
title_full | Viral hepatitis in 2021: The challenges remaining and how we should tackle them |
title_fullStr | Viral hepatitis in 2021: The challenges remaining and how we should tackle them |
title_full_unstemmed | Viral hepatitis in 2021: The challenges remaining and how we should tackle them |
title_short | Viral hepatitis in 2021: The challenges remaining and how we should tackle them |
title_sort | viral hepatitis in 2021: the challenges remaining and how we should tackle them |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8793011/ https://www.ncbi.nlm.nih.gov/pubmed/35125820 http://dx.doi.org/10.3748/wjg.v28.i1.76 |
work_keys_str_mv | AT dunnrebecca viralhepatitisin2021thechallengesremainingandhowweshouldtacklethem AT wettenaaron viralhepatitisin2021thechallengesremainingandhowweshouldtacklethem AT mcphersonstuart viralhepatitisin2021thechallengesremainingandhowweshouldtacklethem AT donnellymhairic viralhepatitisin2021thechallengesremainingandhowweshouldtacklethem |